cas 1442437-21-9|| where to buy 4-hydroxy-6-oxo-1H-pyridazine-3-carboxylic acid

製品名:4-hydroxy-6-oxo-1H-pyridazine-3-carboxylic acid

IUPAC Name:4-hydroxy-6-oxo-1,6-dihydropyridazine-3-carboxylic acid

包装単位	有効在庫	価格（USD）
CM325395-5g	in stock	ȖŞǑ
CM325395-10g	in stock	Ūƃȯ
CM325395-25g	in stock	ǑƥǑ

研究開発用専用.

問い合わせフォーム

化学物質名

CAS番号

数量*

要求仕様*
（アッセイ %、材料グレード等）

お名前*

連絡先Eメールアドレス*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 1442437-21-9 regularly via the above email.

追記事項

Verification code*

refresh

: CAS番号:1442437-21-9; 分子式:C5H4N2O4; 融点:-; SMILESコード:O=C(C(C(O)=C1)=NNC1=O)O; 密度:

: カタログ番号:CM325395; 分子量:156.1; 沸点:; MDL番号:MFCD30489098; 保管方法:

: Pyridazines; Pyridazine, also known as o-diazobenzene, is a six-membered heterocyclic compound containing two nitrogen heteroatoms in the 1 and 2 positions with a special structure and a wide biological activity. Pyridazine is more and more popular in drug development, and a variety of pyridazine drugs have been developed and marketed. From the perspective of the therapeutic field, pyridazine drug molecules are mainly used for tumor treatment, but also involve in many therapeutic fields such as inflammation, hypertension and cardiovascular disease. With the increase and in-depth of research, pyridazine drugs will play more roles in the treatment of diseases.

: Deucravacitinib; BMY announced new four-year Sotyktu (deucravacitinib) data demonstrating durable response rates and consistent safety in moderate-to-severe plaque psoriasis. Deucravacitinib is a specific, oral, intracellular TYK2 inhibitor that targets immune responses driven by type 1 IFN and IL-23 that contribute to psoriasis pathogenesis, including IL-17 production and Th1/Th17 polarization.